Sayone Thihalolipavan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sayone Thihalolipavan has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Charles K. Yu
Kaiser Permanente, San Diego Medical Center, Department of Emergency Medicine, San Diego, California
1 shared publication - Christopher A. Kahn
University of California, San Diego, Department of Emergency Medicine, La Jolla, California
1 shared publication - Donnie Salamanca
Coronado Unified School District 201 Sixth Street Coronado CA 92118
1 shared publication - Howard Taras
Division of Community Pediatrics, University of California, San Diego, La Jolla, CA 92093-0927, USA
1 shared publication - Jeff Lapoint
New York City Poison Control Center, 455 First Ave, New York, 10016, United States
1 shared publication - John D. Malone
Epidemiology and Immunization Services Branch Health and Human Services Agency County of San Diego, 3851 Rosecrans Street, Room Y15 San Diego CA 92110
1 shared publication
Latest Publications
- 3 August 2022
- Published by Wiley in Journal of School Health
- Vol. 92 (12) , 1123-1127
COVID ‐19 Rapid Antigen Testing Implementation in California K‐12 Schools
- 3 August 2022
- Published by Wiley in Journal of School Health
- Vol. 92 (12) , 1123-1127
COVID ‐19 Rapid Antigen Testing Implementation in California K‐12 Schools
- Open Access
- 5 March 2018
- Published by Western Journal of Emergency Medicine in Western Journal of Emergency Medicine
- Vol. 19 (2) , 380-386
Cannabinoid Hyperemesis Syndrome: Public Health Implications and a Novel Model Treatment Guideline
Introduction: Cannabinoid hyperemesis syndrome (CHS) is an entity associated with cannabinoid overuse. CHS typically presents with cyclical vomiting, diffuse abdominal pain, and relief with hot showers. Patients often present to the emergency department (ED) repeatedly and undergo extensive evaluations including laboratory examination, advanced imaging, and in some cases unnecessary procedures. They are exposed to an array of pharmacologic interventions including opioids that not only lack evidence, but may also be harmful.This paper presents a novel treatment guideline that highlights the identification and diagnosis of CHS and summarizes treatment strategies aimed at resolution of symptoms, avoidance of unnecessary opioids, and ensuring patient safety.Methods: The San Diego Emergency Medicine Oversight Commission in collaboration with the County of San Diego Health and Human Services Agency and San Diego Kaiser Permanente Division of Medical Toxicology created an expert consensus panel to establish a guideline to unite the ED community in the treatment of CHS. Results: Per the consensus guideline, treatment should focus on symptom relief and education on the need for cannabis cessation. Capsaicin is a readily available topical preparation that is reasonable to use as first-line treatment. Antipsychotics including haloperidol and olanzapine have been reported to provide complete symptom relief in limited case studies. Conventional antiemetics including antihistamines, serotonin antagonists, dopamine antagonists and benzodiazepines may have limited effectiveness. Emergency physicians should avoid opioids if the diagnosis of CHS is certain and educate patients that cannabis cessation is the only intervention that will provide complete symptom relief.Conclusion: An expert consensus treatment guideline is provided to assist with diagnosis and appropriate treatment of CHS. Clinicians and public health officials should identity and treat CHS patients with strategies that decrease exposure to opioids, minimize use of healthcare resources, and maximize patient safety.
- 5 March 2018
- Published by Western Journal of Emergency Medicine in Western Journal of Emergency Medicine
- Vol. 19 (2) , 380-386
Open AccessCannabinoid Hyperemesis Syndrome: Public Health Implications and a Novel Model Treatment Guideline
Introduction: Cannabinoid hyperemesis syndrome (CHS) is an entity associated with cannabinoid overuse. CHS typically presents with cyclical vomiting, diffuse abdominal pain, and relief with hot showers. Patients often present to the emergency department (ED) repeatedly and undergo extensive evaluations including laboratory examination, advanced imaging, and in some cases unnecessary procedures. They are exposed to an array of pharmacologic interventions including opioids that not only lack evidence, but may also be harmful.This paper presents a novel treatment guideline that highlights the identification and diagnosis of CHS and summarizes treatment strategies aimed at resolution of symptoms, avoidance of unnecessary opioids, and ensuring patient safety.Methods: The San Diego Emergency Medicine Oversight Commission in collaboration with the County of San Diego Health and Human Services Agency and San Diego Kaiser Permanente Division of Medical Toxicology created an expert consensus panel to establish a guideline to unite the ED community in the treatment of CHS. Results: Per the consensus guideline, treatment should focus on symptom relief and education on the need for cannabis cessation. Capsaicin is a readily available topical preparation that is reasonable to use as first-line treatment. Antipsychotics including haloperidol and olanzapine have been reported to provide complete symptom relief in limited case studies. Conventional antiemetics including antihistamines, serotonin antagonists, dopamine antagonists and benzodiazepines may have limited effectiveness. Emergency physicians should avoid opioids if the diagnosis of CHS is certain and educate patients that cannabis cessation is the only intervention that will provide complete symptom relief.Conclusion: An expert consensus treatment guideline is provided to assist with diagnosis and appropriate treatment of CHS. Clinicians and public health officials should identity and treat CHS patients with strategies that decrease exposure to opioids, minimize use of healthcare resources, and maximize patient safety.